IP Library › Granted Patent US 12,502,424

Granted Patent B2

US 12,502,424 · App. 18/654,557 · Granted Dec 23, 2025

Compositions for use in treatment of acne

Inventors: Nadège Arnaud Barbe (Paris, FR); Danilo Casimiro (Cambridge, MA); Andreas Karlsson (Paris, FR); Isabelle Legastelois (Paris, FR); Noëlle Mistretta (Paris, FR); Geneviève Renauld (Paris, FR); Bachra Mohamed Rokbi (Paris, FR); Khang Tran (Cambridge, MA); Monica Wu (Cambridge, MA)

Assignee: SANOFI PASTEUR INC.

A61K39/05 A61P37/04 C07K14/005 C07K14/195 A61K2039/53 A61K2039/6018 A61K2039/70 C07K2319/03

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,502,424
App. No.: 18/654,557
Granted: Dec 23, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes . The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

Claims (147)

1 . A nucleic acid comprising a nucleotide sequence encoding a modified Cutibacterium acnes ( C. acnes ) Christie-Atkins-Munch-Petersen factor 2 (CAMP2) polypeptide, wherein the modified C. acnes CAMP2 polypeptide comprises an amino acid sequence comprising a C. acnes CAMP2 polypeptide sequence and a transmembrane domain sequence, wherein the nucleic acid is a messenger RNA (mRNA).

2 . The nucleic acid of claim 1 , wherein:

(A) (a) the transmembrane domain sequence is positioned at the C terminus of the modified C. acnes CAMP2 polypeptide; and/or

(b) the transmembrane domain sequence comprises a viral transmembrane domain sequence, which is selected from the group consisting of: an influenza hemagglutinin (HA) transmembrane domain sequence, a SARS COV-2 spike transmembrane domain sequence, a VZV gB transmembrane domain sequence, a VZV gE transmembrane domain sequence, a VZV gI transmembrane domain sequence, a VZV gK transmembrane domain sequence, a measles F-protein transmembrane domain sequence, a rubella E1 protein transmembrane domain sequence, a rubella E2 protein transmembrane domain sequence, a mumps F-protein transmembrane domain sequence, an Ebola GP protein transmembrane domain sequence and a rabies transmembrane domain sequence; and/or

(B) the modified C. acnes CAMP2 polypeptide comprises a non-native secretion signal peptide sequence wherein:

(a) the secretion signal peptide sequence is positioned at the N terminus of the modified C. acnes CAMP2 polypeptide; and/or

(b) the secretion signal peptide sequence is a viral secretion signal peptide sequence, which is selected from the group consisting of: an influenza hemagglutinin (HA) secretion signal peptide sequence, a SARS COV-2 spike secretion signal peptide sequence, a VZV gB secretion signal peptide sequence, a VZV gE secretion signal peptide sequence, a VZV gI secretion signal peptide sequence, a VZV gK secretion signal peptide sequence, a measles F-protein secretion signal peptide sequence, a rubella E1 protein secretion signal peptide sequence, a rubella E2 protein secretion signal peptide sequence, a mumps F-protein secretion signal peptide sequence, an Ebola GP protein secretion signal peptide sequence, a smallpox 6 kDa IC protein secretion signal peptide sequence and a rabies G protein secretion signal peptide sequence.

3 . The nucleic acid of claim 1 , wherein the transmembrane domain comprises an amino acid sequence selected from the group consisting of sequences set forth by SEQ ID NO: 208-209 and 241-253.

4 . The nucleic acid of claim 1 , wherein

the mRNA comprises a 5′ cap, at least one 5′ untranslated region (5′ UTR), at least one 3′ untranslated region (3′ UTR), and/or at least one polyadenylation (poly(A)) sequence.

5 . The nucleic acid of claim 1 , wherein:

(a) the modified C. acnes CAMP2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 207 and SEQ ID NO: 5-9, or a sequence having at least 60% identity thereto; and/or

(b) the nucleic acid comprises a nucleotide sequence selected from the group consisting of sequences set forth by SEQ ID NO: 90-94 and SEQ ID NO: 391-392, or a sequence having at least 50% identity thereto; and/or

(i) a 5′ cap with the following structure:

(ii) a 5′ untranslated region (5′ UTR) having the nucleic acid sequence according to SEQ ID NO: 265;

(iii) a protein coding region having the nucleic acid sequence selected from the group consisting of sequences set forth by SEQ ID NO: 90-91 and SEQ ID NO: 391-392;

(iv) a 3′ untranslated region (3′ UTR) having the nucleic acid sequence according to SEQ ID NO: 266; and

(v) a poly A tail.

6 . A composition comprising the nucleic acid of claim 1 .

7 . The composition of claim 6 , wherein the composition further comprises one or more of:

(i) a nucleic acid comprising a nucleotide sequence encoding a C. acnes dermatan sulfate-adhesin 1 (DsA1) polypeptide;

(ii) a nucleic acid comprising a nucleotide sequence encoding a C. acnes dermatan sulfate-adhesin 2 (DsA2) polypeptide;

(iii) a nucleic acid comprising a nucleotide sequence encoding a C. acnes putative iron-transport protein (PITP) polypeptide;

(iv) a nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2 polypeptide; and

(v) a nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2/PITP polypeptide.

8 . The composition of claim 6 , wherein the composition comprises:

(A) a first mRNA comprising or consisting of the following structural elements:

(i) a 5′ cap;

(ii) a 5′ UTR having the nucleic acid sequence according to SEQ ID NO: 265;

(iii) a protein coding region having the nucleic acid sequence according to SEQ ID NO: 91;

(iv) a 3′ UTR having the nucleic acid sequence according to SEQ ID NO: 266; and

(v) a poly A tail;

(B) a second mRNA comprising or consisting of the following structural elements:

(i) a 5′ cap;

(ii) a 5′ UTR having the nucleic acid sequence according to SEQ ID NO: 265;

(iii) a protein coding region having the nucleic acid sequence according to SEQ ID NO: 113;

(iv) a 3′ UTR having the nucleic acid sequence according to SEQ ID NO: 266; and

(v) a poly A tail; and

(i) a 5′ cap;

(ii) a 5′ UTR having the nucleic acid sequence according to SEQ ID NO: 265;

(iii) a protein coding region having the nucleic acid sequence according to SEQ ID NO: 115;

(iv) a 3′ UTR having the nucleic acid sequence according to SEQ ID NO: 266; and

(v) a poly A tail;

wherein the 5′ cap has the following structure:

9 . The composition of claim 6 , wherein:

the composition comprises a total of about 45 μg, about 120 μg, or about 225 μg of the one or more nucleic acid(s).

10 . A composition comprising a nucleic acid comprising a nucleotide sequence encoding a C. acnes CAMP2 polypeptide and one or more of:

(i) a nucleic acid comprising a nucleotide sequence encoding a C. acnes DsA1 polypeptide;

(ii) a nucleic acid comprising a nucleotide sequence encoding a C. acnes DsA2 polypeptide;

(iii) a nucleic acid comprising a nucleotide sequence encoding a C. acnes PITP polypeptide;

(iv) a nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2 polypeptide; and

(v) a nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2/PITP polypeptide.

11 . The composition of claim 10 , wherein the composition comprises the nucleic acid according to (iii) and/or the nucleic acid according to (iv).

12 . The composition of claim 10 , wherein

any two or more nucleic acids are located on the same nucleic acid molecule or on different nucleic acid molecules.

13 . The composition of claim 10 , wherein:

(a) the C. acnes CAMP2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 203, SEQ ID NO: 43-58, SEQ ID NO: 1-4, SEQ ID NO: 10-16 and SEQ ID NO: 339-363 or a sequence having at least 60% identity thereto;

(b) the C. acnes DsA1 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 204, SEQ ID NO: 17-19 and SEQ ID NO: 59-61, or a sequence having at least 75% identity thereto;

(c) the C. acnes DsA2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 205, SEQ ID NO: 20-27 and SEQ ID NO: 62-69 or a sequence having at least 75% identity thereto;

(d) the C. acnes PITP polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 206, SEQ ID NO: 31-37, and SEQ ID NO: 73-79 or a sequence having at least 75% identity thereto;

(e) the chimeric C. acnes DsA1/DsA2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 28-30, SEQ ID NO: 39, SEQ ID NO: 70-72 and SEQ ID NO: 81, or a sequence having at least 90% identity thereto; and/or

(f) the chimeric C. acnes DsA1/DsA2/PITP polypeptide comprises (i) a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 28-30, SEQ ID NO:

39, SEQ ID NO: 70-72 and SEQ ID NO: 81, or a sequence having at least 90% identity thereto; and (ii) a PITP polypeptide sequence.

14 . A nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide, wherein the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises:

(a) a chimeric C. acnes DsA1/DsA2 polypeptide;

(b) an immunogenic fragment of a C. acnes PITP polypeptide; and

15 . The nucleic acid comprising a nucleotide sequence encoding a chimeric C acnes DsA1/DsA2/PITP/CAMP2 polypeptide of claim 14 , wherein:

i, the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises a first conserved sub-domain (CSD1) of a C. acnes DsA1 polypeptide, a second conserved sub-domain (CSD2) of a C. acnes DsA2 polypeptide and a third conserved sub-domain (CSD3) of a C. acnes DsA1 polypeptide;

ii, the immunogenic fragment of a C. acnes PITP polypeptide in (b) comprising an extended neocarzinostatin family domain (ENFD) of a C. acnes PITP polypeptide comprises the sequence corresponding to amino acid residues 1-133 or residues 1-146 of SEQ ID NO: 73 or a sequence having at least 90% identity thereto; and/or

iii. (c) is (1) a C. acnes CAMP2 polypeptide; or (2) an immunogenic fragment of a C. acnes CAMP2 polypeptide comprising a N-terminal domain of a C. acnes CAMP2 polypeptide.

16 . The nucleic acid of claim 14 , wherein:

(i) the chimeric C acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 374-375;

(ii) the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises a sequence according to SEQ ID NO: 373 and a transmembrane domain sequence,

(iii) the nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 377-382 and 384-389; and/or

(iv) the nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises a sequence according to SEQ ID NO: 384 and a sequence according to SEQ ID NO: 395; or a sequence according to SEQ ID NO: 385 and a sequence according to SEQ ID NO: 396.

17 . A chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide encoded by the nucleic acid of claim 14 .

18 . A composition, optionally an immunogenic composition, comprising the nucleic acid as defined in claim 14 .

19 . A composition, optionally an immunogenic composition, comprising the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide as defined in claim 17 .

20 . An immunogenic composition comprising a nucleic acid comprising a nucleotide sequence encoding a C. acnes CAMP2 polypeptide, wherein the nucleic acid is a mRNA.

21 . A method of treating or preventing C. acnes infection in a subject, the method comprising administering the nucleic acid of claim 1 to the subject.

22 . A method of treating or preventing at least one symptom of a C. acnes infection in a subject, the method comprising administering the composition of claim 10 to the subject.

23 . A method of treating or preventing at least one symptom of a C. acnes infection in a subject, the method comprising administering the nucleic acid of claim 14 to the subject.

24 . A method of treating or preventing at least one symptom of a C. acnes infection in a subject, the method comprising administering the polypeptide of claim 17 to the subject.

25 . A method of treating or preventing at least one symptom of a C. acnes infection in a subject, the method comprising administering the immunogenic composition of claim 20 to the subject.

26 . The nucleic acid of claim 1 , wherein the mRNA is unmodified.

27 . The nucleic acid of claim 1 , wherein the mRNA comprises at least one chemical modification.

28 . The nucleic acid of claim 1 , wherein the mRNA is a self-replicating mRNA.

29 . The nucleic acid of claim 1 , wherein the mRNA is a non-replicating mRNA.

30 . The nucleic acid of claim 5 , wherein the polyA tail comprises at least 75 adenosine nucleotides or at least 100 adenosine nucleotides.

31 . The composition of claim 6 , wherein the composition is in a frozen liquid form or in a lyophilized form.

32 . The composition of claim 7 , wherein:

the modified C. acnes CAMP2 polypeptide comprises a sequence having at least 60% identity to SEQ ID NO: 207;

the chimeric C. acnes DsA1/DsA2 polypeptide comprises a sequence having at least 90% identity to SEQ ID NO: 70; and

the C. acnes PITP polypeptide comprises a sequence having at least 75% identity to SEQ ID NO: 73.

33 . The composition of claim 6 , wherein the composition further comprises a nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2 polypeptide and a nucleic acid comprising a nucleotide sequence encoding a C. acnes PITP polypeptide, wherein:

the modified C. acnes CAMP2 polypeptide comprises or consists of a sequence according to SEQ ID NO: 207;

the chimeric C. acnes DsA1/DsA2 polypeptide comprises or consists of a sequence according to SEQ ID NO: 70; and

the C. acnes PITP polypeptide comprises or consists of a sequence according to SEQ ID NO: 73.

34 . The composition of claim 7 , wherein:

the nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide comprises a sequence having at least 50% identity to SEQ ID NO: 91;

the nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide comprises a sequence having at least 75% identity to SEQ ID NO: 113; and

the nucleotide sequence encoding the C. acnes PITP polypeptide comprises a sequence having at least 50% identity to SEQ ID NO: 115.

35 . The composition of claim 6 , wherein the composition further comprises a nucleic acid comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2 polypeptide and a nucleic acid comprising a nucleotide sequence encoding a C. acnes PITP polypeptide, wherein:

the nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide comprises or consists of a sequence according to SEQ ID NO: 91;

the nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide comprises or consists of a sequence according to SEQ ID NO: 113; and

the nucleotide sequence encoding the C. acnes PITP polypeptide comprises or consists of a sequence according to SEQ ID NO: 115.

36 . The composition of claim 6 , wherein the composition further comprises a lipid nanoparticle (LNP).

37 . The composition of claim 36 , wherein any one or more nucleic acids are encapsulated in the LNP.

38 . The composition of claim 7 , wherein any two or more nucleic acids are co-encapsulated in a single LNP.

39 . The composition of claim 33 , wherein the nucleic acid comprising a nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide, the nucleic acid comprising a nucleotide sequence encoding the C. acnes PITP polypeptide, and the nucleic acid comprising a nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide are encapsulated in an LNP.

40 . The composition of claim 33 , wherein the nucleic acid comprising a nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide, the nucleic acid comprising a nucleotide sequence encoding the C. acnes PITP polypeptide, and the nucleic acid comprising a nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide are co-encapsulated in a single LNP.

41 . The composition of claim 33 , wherein the nucleic acid comprising a nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide, the nucleic acid comprising a nucleotide sequence encoding the C. acnes PITP polypeptide, and the nucleic acid comprising a nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide are present in a weight ratio of 1:1:1.

42 . The composition of claim 35 , wherein the nucleic acid comprising a nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide, the nucleic acid comprising a nucleotide sequence encoding the C. acnes PITP polypeptide, and the nucleic acid comprising a nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide are co-encapsulated in a single LNP.

43 . The composition of claim 35 , wherein the nucleic acid comprising a nucleotide sequence encoding the modified C. acnes CAMP2 polypeptide, the nucleic acid comprising a nucleotide sequence encoding the C. acnes PITP polypeptide, and the nucleic acid comprising a nucleotide sequence encoding the chimeric C. acnes DsA1/DsA2 polypeptide are present in a weight ratio of 1:1:1.

44 . The composition of claim 7 , wherein any two or more nucleic acids are encapsulated in separate LNPs.

45 . The composition of claim 36 , wherein: the LNP comprises at least one cationic lipid and wherein the cationic lipid is selected from the group consisting of OF-02, cKK-E10, IM-001, IS-001 and GL-HEPES-E3-E12-DS-4-E10; and/or

the LNP comprises a polyethylene glycol (PEG) conjugated (PEGylated) lipid, a cholesterol-based lipid, and a helper lipid.

46 . The composition of claim 45 , wherein the LNP comprises GL-HEPES-E3-E12-DS-4-E10, DMG-PEG2000, cholesterol and DOPE.

47 . The composition of claim 46 , wherein the LNP comprises GL-HEPES-E3-E12-DS-4-E10 at a molar ratio of 40%, DMG-PEG2000 at a molar ratio of 1.5%, cholesterol at a molar ratio of 28.5%, and DOPE at a molar ratio of 30%.

48 . The composition of claim 10 , wherein the composition is an immunogenic composition.

49 . The composition of claim 10 , wherein the composition is in a frozen liquid form or in a lyophilized form.

50 . The composition of claim 10 , wherein the C. acnes DsA1 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 204, SEQ ID NO: 17-19 and SEQ ID NO: 59-61, or a sequence having at least 75% identity thereto.

51 . The composition of claim 10 , wherein the C. acnes DsA2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 205, SEQ ID NO: 20-27 and SEQ ID NO: 62-69 or a sequence having at least 75% identity thereto.

52 . The composition of claim 10 , wherein the C. acnes PITP polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 206, SEQ ID NO: 31-37, and SEQ ID NO: 73-79 or a sequence having at least 75% identity thereto.

53 . The composition of claim 10 , wherein the chimeric C. acnes DsA1/DsA2 polypeptide comprises a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 28-30, SEQ ID NO: 39, SEQ ID NO: 70-72 and SEQ ID NO: 81, or a sequence having at least 90% identity thereto.

54 . The composition of claim 10 , wherein the chimeric C. acnes DsA1/DsA2/PITP polypeptide comprises (i) a sequence selected from the group consisting of sequences set forth by SEQ ID NO: 28-30, SEQ ID NO: 39, or SEQ ID NO: 70-72 and SEQ ID NO: 81, or a sequence having at least 90% identity thereto; and (ii) a PITP polypeptide sequence.

55 . The nucleic acid of claim 14 , wherein the immunogenic fragment of a C. acnes PITP polypeptide of (b) comprises an extended neocarzinostatin family domain (ENFD) of a C. acnes PITP polypeptide.

56 . The nucleic acid of claim 15 , wherein the chimeric C. acnes DsA1/DsA2 polypeptide of (a) comprises a sequence according to SEQ ID NO: 70, or a sequence having at least 90% identity thereto.

57 . The nucleic acid of claim 15 , wherein the C. acnes CAMP2 polypeptide of (c) (1) comprises SEQ ID NO: 203 or a sequence having at least 90% identity thereto.

58 . The nucleic acid of claim 15 , wherein the chimeric C. acnes DsA1/DsA2/PITP/CAMP2 polypeptide comprises a transmembrane domain sequence.

59 . The nucleic acid of claim 58 , wherein the transmembrane domain sequence comprises an amino acid sequence according to SEQ ID NO: 84.

60 . The composition of claim 11 , wherein the C. acnes CAMP2 polypeptide comprises a sequence according to SEQ ID NO: 203 or a sequence having at least 60% identity thereto; the chimeric C. acnes DsA1/DsA2 polypeptide comprises a sequence according to SEQ ID NO: 70 or a sequence having at least 90% identity thereto; and the C. acnes PITP polypeptide comprises a sequence according to SEQ ID NO: 73 or a sequence having at least 75% identity thereto.

61 . A composition comprising:

a messenger RNA (mRNA) comprising a nucleotide sequence encoding a modified C. acnes CAMP2 polypeptide comprising or consisting of a sequence according to SEQ ID NO: 207;

a mRNA comprising a nucleotide sequence encoding a chimeric C. acnes DsA1/DsA2 polypeptide comprising or consisting of a sequence according to SEQ ID NO: 70; and

a mRNA comprising a nucleotide sequence encoding a C. acnes PITP polypeptide comprising or consisting of a sequence according to SEQ ID NO: 73,

wherein the mRNAs are encapsulated in an LNP.

62 . The composition of claim 61 , wherein the mRNAs are co-encapsulated in the same LNP.

63 . The composition of claim 61 , wherein the mRNAs are present in a weight ratio of 1:1:1.

64 . The composition of claim 61 , wherein the mRNAs are present in a weight ratio of 1:1:1 and are co-encapsulated in the same LNP.

65 . A method of generating an immune response against a C. acnes infection in a subject, the method comprising administering the composition of claim 10 to the subject.

66 . A method of generating an immune response against a C. acnes infection in a subject, the method comprising administering the nucleic acid of claim 14 to the subject.

67 . A method of generating an immune response against a C. acnes infection in a subject, the method comprising administering the polypeptide of claim 17 to the subject.

68 . A method of generating an immune response against a C. acnes infection in a subject, the method comprising administering the immunogenic composition of claim 20 to the subject.

Assignments (5)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2025

From: CASIMIRO, DANILO; TRAN, KHANG; WU, MONICA

To: SANOFI

Reel/Frame 072570/0524 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2025

From: ARNAUD BARBE, NADÈGE; KARLSSON, ANDREAS; LEGASTELOIS, ISABELLE; MISTRETTA, NOËLLE; RENAULD, GENEVIÈVE; MOHAMED ROKBI, BACHRA

To: SANOFI PASTEUR

Reel/Frame 072570/0641 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2025

From: SANOFI PASTEUR

To: SANOFI

Reel/Frame 072570/0707 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2025

From: SANOFI

To: SANOFI PASTEUR INC.

Reel/Frame 072570/0783 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2025

From: SANOFI

To: SANOFI PASTEUR INC.

Reel/Frame 070857/0978 →

Priority Claims (2)

EP 23306076 · Jun 29, 2023 · regional

EP 23306927 · Nov 8, 2023 · regional

Continuity (2)

Provisional Application 63464523 · May 5, 2023

Related Publication 20240374698A1 · Nov 14, 2024

References Cited (68)

US 8784830B2 · Hasumi et al. · 2014 [cited by applicant]

US 9340769B2 · Gallo et al. · 2016 [cited by applicant]

US 9528997B2 · Rogéet al. · 2016 [cited by applicant]

US 9637525B2 · Foster et al. · 2017 [cited by applicant]

US 9669089B2 · Thess et al. · 2017 [cited by applicant]

US 9675668B2 · Bancel et al. · 2017 [cited by applicant]

US 9782462B2 · Bancel et al. · 2017 [cited by applicant]

US 9895432B2 · Hasumi et al. · 2018 [cited by applicant]

US 10030053B2 · Compans et al. · 2018 [cited by applicant]

US 10323078B2 · Dupin et al. · 2019 [cited by applicant]

US 10364473B2 · Li et al. · 2019 [cited by applicant]

US 10426825B2 · Hasumi et al. · 2019 [cited by applicant]

US 10988754B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]

US 11020468B2 · Hasumi et al. · 2021 [cited by applicant]

US 11129885B2 · Luo · 2021 [cited by applicant]

US 11512118B2 · Foster et al. · 2022 [cited by applicant]

US 20020142978A1 · Raz et al. · 2002 [cited by applicant]

US 20200038499A1 · Narayanan et al. · 2020 [cited by applicant]

US 20200392482A1 · Zhang et al. · 2020 [cited by applicant]

US 20200399322A1 · Baumhof et al. · 2020 [cited by applicant]

US 20210123092A1 · Li et al. · 2021 [cited by applicant]

US 20220040281A1 · Schwendt et al. · 2022 [cited by applicant]

US 20220040285A1 · Weissman et al. · 2022 [cited by applicant]

US 20230145420A1 · Vukovich et al. · 2023 [cited by applicant]

US 20240139302A1 · Selak · 2024 [cited by examiner]

CZ 25164U1 · 2013 [cited by applicant]

WO WO2001081581A2 · 2001 [cited by applicant]

WO WO2003033515A1 · 2003 [cited by applicant]

WO WO2010005474A1 · 2010 [cited by applicant]

WO WO2012006372A1 · 2012 [cited by applicant]

WO WO2013006825A1 · 2013 [cited by applicant]

WO WO2017019982A1 · 2017 [cited by applicant]

WO WO2018175783A1 · 2018 [cited by applicant]

WO WO2018176031A1 · 2018 [cited by examiner]

WO WO2019079612A1 · 2019 [cited by applicant]

WO WO2019079618A2 · 2019 [cited by applicant]

WO WO2021165543A1 · 2021 [cited by applicant]

WO WO2022099003A1 · 2022 [cited by examiner]

WO WO2022204491A1 · 2022 [cited by applicant]

WO WO2023214082A2 · 2023 [cited by applicant]

WO WO2024133515A1 · 2024 [cited by applicant]

WO WO2024188165A1 · 2024 [cited by applicant]

Liu PF, Nakatsuji T, Zhu W, Gallo RL, Huang CM. Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine. Apr. 12, 2011;29(17):3230-8. … [cited by examiner]

Embry A, Meng X, Cantwell A, Dube PH, Xiang Y. Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion. Vaccine. Jul. 26, 2011;29(… [cited by examiner]

NCBI Reference Sequence: WP_002518322.1 (2023); note that this protein is identical to AAT82444.1, 2014 (Year: 2023). [cited by examiner]

Grange et al., “Characterization of a Propionibacterium acnes Surface Protein as a Fibrinogen-Binding Protein”, Sci. Rep., Jul. 25, 2017, 7(1): 6428. [cited by applicant]

Jahns et al., “An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study”, Br. J. Dermatol., Jul. 2012, 167(1): 50-58. Epub Jun. 1, 2012. [cited by applicant]

Liu et al., “Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris”, Vaccine, Apr. 12, 2011, 29(17): 3230-3238. Epub Feb. 26, 2011. [cited by applicant]

Lodes et al., “Variable expression of immunoreactive surface proteins of Propionibacterium acnes”, Microbiology (Reading), Dec. 2006, 152(Pt 12): 3667-3681. [cited by applicant]

Maruggi et al., “Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens”, Vaccine, Jan. 5, 2017, 35(2): 361-368. Epub Dec. 7, 2016. [cited by applicant]

McDowell et al., “Propionibacterium acnes types I and II represent phylogenetically distinct groups”, J Clin Microbiol., Jan. 2005, 43(1): 326-334. [cited by applicant]

McDowell et al., “A new phylogenetic group of Propionibacterium acnes”, J. Med. Microbiol., Feb. 2008, 57(Pt 2): 218-224. [cited by applicant]

McDowell et al., “A novel multilocus sequence typing scheme for the opportunistic pathogen Propionibacterium acnes and characterization of type I cell surface-associated antigens”, Microbiology (Reading), Jul. 2011, 157… [cited by applicant]

McDowell et al., “An expanded multilocus sequence typing scheme for propionibacterium acnes: investigation of ‘pathogenic’, ‘commensal’ and antibiotic resistant strains”, PLoS One, 2012, 7(7): e41480. Epub Jul. 30, 2012. [cited by applicant]

McDowell et al., “The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution”, PLoS One, Sep. 13, 2013, 8(9): e70897. [cited by applicant]

McLaughlin et al., “Propionibacterium acnes and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies”, Microorganisms, May 13, 2019, 7(5): 128. [cited by applicant]

Nagata et al., “Immunohistochemical Detection of Propionibacterium acnes in the Retinal Granulomas in Patients with Ocular Sarcoidosis”, Sci. Rep., Nov. 9, 2017, 7(1): 15226. [cited by applicant]

Nakatsuji et al., “Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris”, PLoS One, Feb. 6, 2008, 3(2): e1551. [cited by applicant]

Nakatsuji et al., “Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment”, PLoS One, Apr. 12, 2011, 6(4): e14797. [cited by applicant]

Parvin et al., “A Therapeutic Oral Vaccine Candidate against Propionibacterium acnes: Preparation and Immunological Evaluation of Nanoparticles Encapsulated Sialidase-CAMP Fusion Protein”, Human and Animal Health, 2020,… [cited by applicant]

Sanofi, “Innovation to drive sustainable growth in Vaccines”, Vaccines Investor Event, Presentation, Jun. 29, 2023. [cited by applicant]

Toyoda et al., “An Overview of Topical Antibiotics for Acne Treatment”, Dermatology, 1998, 196(1): 130-134. [cited by applicant]

Tunney et al., “Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene”, J. Clin. Microbiol., Oct. 1999, 37(10): 3281-3290. [cited by applicant]

Valanne et al., “CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II”, Microbiology (Reading), May 2005, 151(Pt 5): 1369-1379. [cited by applicant]

Wang et al., “The Anti-Inflammatory Activities of Propionibacterium acnes CAMP Factor-Targeted Acne Vaccines”, J. Invest. Dermatol., Nov. 2018, 138(11): 2355-2364. Epub Jun. 30, 2018. [cited by applicant]

Xue et al., “RNA encoding the MPT83 antigen induces protective immune responses against [cited by applicant]

Yang et al., “Specific humoral immune response induced by propionibacterium acnes can prevent Actinobacillus pleuropneumoniae infection in mice”, Clin. Vaccine Immunol., Mar. 2014, 21(3): 407-416. Epub Jan. 15, 2014. [cited by applicant]

Extended European Search Report for European Patent Application No. 23306076.3, dated Dec. 22, 2023. [cited by applicant]